Methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: A meta-analysis

Clinical Genetics

Volumn 69, Issue 4, 2006, Pages 327-336

  Zintzaras, Elias ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

A1298C; Breast cancer; C677T; Meta analysis; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ALLELE; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; DNA EXTRACTION; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETICS, POPULATION; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 33645472458     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2006.00605.x     Document Type: Article

References (38)

1. Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med 2005: 9: 208-221.
2. Kim YI. Folate and cancer prevention: A new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev 1999: 57: 314-321.
3. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001: 22: 195-201.
4. Blount BC, Mack MM, Wehr CM et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997: 7: 3290-3295.
5. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995: 10: 111-113.
6. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998: 64: 169-172.
7. Weir BS. Genetic data analysis II: Methods for discrete population genetic data. Sunderland, MA: Sinauer Associates, 1996.
8. Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I. The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: A meta-analysis. J Hum Genet 2005: 50: 267-275.
9. Zintzaras E, Hadjigeorgiou GM. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis. J Hum Genet 2004: 49: 474-481.
10. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2004: 24: 1 -15.
11. Zintzaras E, Ioannidis JP. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 2005: 21: 3672-3673.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003: 327: 557-560.
13. Zintzaras E, Hadjigeorgiou GM. The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: A meta-analysis. J Hum Genet 2005: 50: 560-566.
14. Zintzaras E, Stefanidis I. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: A meta-analysis. J Hum Genet 2005: 50: 84-91.
15. Ioannidis J, Lau J. Evolution of treatment effects over time: Empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci USA 2001: 98: 831-836.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994: 50: 1088-1101.
17. Ioannidis JP, Ntzani EE, Trikalinos TA. 'Racial' differences in genetic effects for complex diseases. Nat Genet 2004: 36: 1312-1318.
18. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT, and breast cancer risk: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2004: 13: 2071-2077.
19. Langsenlehner U, Krippl P, Renner W et al. The common 677C>T gene polymorphism of methylenetetrahydrofolate reductase gene is not associated with breast cancer risk. Breast Cancer Res Treat 2003: 81: 169-172.
20. Grieu F, Powell B, Beilby J, Iacopetta B. Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype. Anticancer Res 2004: 24: 3215-3219.
21. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005: 10: 57-65.
22. Deligezer U, Akisik EE, Dalay N. Homozygosity at the C677T of the MTHFR gene is associated with increased breast cancer risk in the Turkish population. In Vivo 2005: 19: 889-893.
23. Lee SA, Kang D, Nishio H et al. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp Mol Med 2004: 36: 116-121.
24. Lin WY, Chou YC, Wu MH et al. The MTHFR C677T polymorphism, estrogen exposure and breast cancer risk: A nested case-control study in Taiwan. Anticancer Res 2004: 24: 3863-3868.
25. Shrubsole MJ, Gao YT, Cai Q et al. MTHFR polymorphisms, dietary folate intake, and breast cancer risk: Results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2004: 13: 190-196.
26. Forsti A, Angelini S, Festa F et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004: 11: 917-922.
27. Chen J, Gammon MD, Chan W et al. One-carbon metabolism, MTHFR polymorphisms, and risk of breast cancer. Cancer Res 2005: 65: 1606-1614.
28. Sharp L, Little J, Schofield AC et al. Folate and breast cancer: The role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 2002: 181: 65-71.
29. Campbell IG, Baxter SW, Eccles DM, Choong DY. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002: 4: R14.
30. Ergul E, Sazci A, Utkan Z, Canturk NZ. Polymorphisms in the MTHFR gene are associated with breast cancer. Tumour Biol 2003: 24: 286-290.
31. Hekim N, Ergen A, Yaylim I et al. No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct 2005 [Epub ahead of print].
32. Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677C→T polymorphism affect cancer risk: Intake recommendations. J Nutr 2003: 133: 3748S-3753S.
33. Choumenkovitch SF, Selhub J, Wilson PW, Rader JI, Rosenberg IH, Jacques PF. Folic acid intake from fortification in United States exceeds predictions. J Nutr 2002: 132: 2792-2798.
34. Singletary KW, Gapstur SM. Alcohol and breast cancer: Review of epidemiologic and experimental evidence and potential mechanisms. JAMA 2001: 286: 2143-2151.
35. Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol 2004: 39: 155-165.
36. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006: 43: 127-137.
37. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol 2004: 16: 19-25.
38. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001: 358: 1356-1360.